Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Down 7.5% – Should You Sell?

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) dropped 7.5% on Friday . The company traded as low as $33.06 and last traded at $33.22. Approximately 99,557 shares were traded during trading, a decline of 90% from the average daily volume of 1,016,120 shares. The stock had previously closed at $35.90.

Analysts Set New Price Targets

Several equities research analysts have issued reports on AGIO shares. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 9th. Leerink Partners cut shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the company from $60.00 to $56.00 in a report on Friday, September 27th. Royal Bank of Canada increased their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research note on Tuesday, December 10th. Raymond James reissued an “outperform” rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, October 10th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a research report on Wednesday, December 18th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $56.33.

Agios Pharmaceuticals Stock Performance

The firm has a market capitalization of $1.92 billion, a price-to-earnings ratio of 2.97 and a beta of 0.87. The company’s fifty day moving average price is $46.77 and its 200 day moving average price is $45.50.

Insider Activity

In other news, insider Tsveta Milanova sold 2,804 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares in the company, valued at approximately $608,395.08. This represents a 12.92 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.93% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Acadian Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the second quarter valued at about $37,000. Quest Partners LLC acquired a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $40,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares in the last quarter. CWM LLC increased its stake in shares of Agios Pharmaceuticals by 554.7% during the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 1,836 shares during the period. Finally, Quantbot Technologies LP bought a new stake in Agios Pharmaceuticals during the third quarter worth approximately $146,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.